OTCMKTS:MYRX - Myrexis Stock Price, Price Target & More

$0.0495 -0.01 (-13.46 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$0.0572
Today's Range$0.0310 - $0.0495
52-Week Range$0.02 - $0.09
Volume15,125 shs
Average Volume13,906 shs
Market Capitalization$1.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.46

About Myrexis (OTCMKTS:MYRX)

Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.

Receive MYRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MYRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MYRX
CUSIPN/A
Phone801-214-7800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares34,480,000

How to Become a New Pot Stock Millionaire

Myrexis (OTCMKTS:MYRX) Frequently Asked Questions

What is Myrexis' stock symbol?

Myrexis trades on the OTCMKTS under the ticker symbol "MYRX."

Who are some of Myrexis' key competitors?

Who are Myrexis' key executives?

Myrexis' management team includes the folowing people:
  • Mr. Jonathan M. Couchman CFA, Chairman, CEO, Pres, CFO and Principal Accounting Officer (Age 48)

Has Myrexis been receiving favorable news coverage?

Media headlines about MYRX stock have trended somewhat positive on Monday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Myrexis earned a news impact score of 0.16 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.54 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Myrexis?

Shares of MYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myrexis' stock price today?

One share of MYRX stock can currently be purchased for approximately $0.0495.

How big of a company is Myrexis?

Myrexis has a market capitalization of $1.97 million.

How can I contact Myrexis?

Myrexis' mailing address is C/O XSTELOS HOLDINGS INC. 630 FIFTH AVENUE SUITE 2260, NEW YORK NY, 10020. The biopharmaceutical company can be reached via phone at 801-214-7800 or via email at [email protected]


MarketBeat Community Rating for Myrexis (MYRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  56
MarketBeat's community ratings are surveys of what our community members think about Myrexis and other stocks. Vote "Outperform" if you believe MYRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Myrexis (OTCMKTS:MYRX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/23/2016 forward)

Earnings

Myrexis (OTCMKTS:MYRX) Earnings History and Estimates Chart

Earnings by Quarter for Myrexis (OTCMKTS:MYRX)

Myrexis (OTCMKTS MYRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2013Q3 2013($0.11)ViewN/AView Earnings Details
9/13/2012Q4 2012($0.16)ViewN/AView Earnings Details
5/10/2012Q3 2012($0.27)ViewN/AView Earnings Details
2/9/2012Q2 2012($0.29)ViewN/AView Earnings Details
11/9/2011Q1 2012($0.27)($0.33)ViewN/AView Earnings Details
9/8/2011Q4 2011($0.35)($0.31)ViewN/AView Earnings Details
5/10/2011Q3 2011($0.55)($0.50)ViewN/AView Earnings Details
2/9/2011Q2 2011($0.45)($0.31)ViewN/AView Earnings Details
11/9/2010Q1 2011($0.51)($0.40)ViewN/AView Earnings Details
9/9/2010Q4 2010($0.51)($0.31)ViewN/AView Earnings Details
5/17/2010Q3 2010($0.55)($0.56)ViewN/AView Earnings Details
2/16/2010Q2 2010($0.45)($0.60)ViewN/AView Earnings Details
11/12/2009Q1 2010($0.44)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Myrexis (OTCMKTS:MYRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/25/2013special$2.862/19/20132/4/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Myrexis (OTCMKTS MYRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 0.29%
Insider Trading History for Myrexis (OTCMKTS:MYRX)

Myrexis (OTCMKTS MYRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Myrexis (OTCMKTS MYRX) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Myrexis (OTCMKTS:MYRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Myrexis (OTCMKTS:MYRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Myrexis (OTCMKTS MYRX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.